Skip to main content
Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
249.85
+0.68 (0.27%)
Feb 21, 2025, 4:00 PM EST - Market closed

Labcorp Holdings Revenue by Segment
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
10.15B 9.91B 9.70B 9.51B 9.41B 9.35B 9.21B 9.13B
Diagnostics Growth
7.82% 5.91% 5.22% 4.19% 2.27% -1.97% -7.39% -9.25%
Drug Development
2.92B 2.85B 2.83B 2.82B 3.51B 4.21B 4.89B 5.65B
Drug Development Growth
-16.80% -32.26% -42.15% -50.00% -38.45% -27.06% -15.94% -3.73%

Operating Income by Segment
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
1.61B 1.60B 1.60B 1.57B 1.59B 1.62B 1.68B 1.78B
Diagnostics Growth
0.95% -1.48% -4.68% -12.13% -21.44% -32.72% -38.97% -38.42%
Drug Development
459.00M 437.20M 425.30M 422.50M 446.50M 546.00M 647.70M 756.40M
Drug Development Growth
2.80% -19.93% -34.34% -44.14% -44.26% -31.60% -20.40% -7.92%
General Corporate Expenses
-268.30M -269.00M -273.20M -382.10M -389.00M -406.80M -396.80M -291.70M

Operating Expense Breakdown
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Selling, General, and Administrative
2.23B 2.17B 2.12B 2.07B 2.12B 2.12B 2.11B 2.09B
Selling, General, and Administrative Growth
5.30% 2.18% 0.89% -0.65% 6.07% 5.87% 4.58% 5.02%
Amortization
256.40M 245.20M 237.20M 226.50M 235.70M 237.10M 246.60M 261.50M
Amortization Growth
8.78% 3.42% -3.81% -13.38% -9.10% -18.69% -22.60% -24.11%
Restructuring and Other
46.00M 52.90M 42.40M 46.60M 50.20M 43.60M 51.20M 79.80M
Restructuring and Other Growth
-8.37% 21.33% -17.19% -41.60% -40.10% -45.43% -28.19% 118.63%
Impairments
5.30M - - 349.30M 349.00M 285.50M 275.30M 272.50M
Impairments Growth
-98.48% - - 28.18% 28.55% - - 22,608.33%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.